Inclusion Criteria:

          -  sign an informed consent before undertaking any trial-related activities;

          -  ≥18 and ≤75 years old;

          -  Multi-line treatment failed Solid Tumors except non small cell lung cancer,including
             Liver Cancer,Gastric Cancer,Esophageal Cancer,Bone and Soft Tissue Tumors,Breast
             Cancer, Bladder Carcinoma,Prostate Carcinoma,Thyroid Cancer, Ovarian Cancer and so on
             diagnosed by licensed pathologist;

          -  multi-line treatment failed patients;

          -  with measurable lesions according to Response Evaluation Criteria In Solid Tumors1.1
             or immune related response criteria standard;

          -  meet the two screening indicators: HLA-A*0201+, NYESO-1+(≥25% by
             immunohistochemistry);

          -  Eastern Cooperative Oncology Group score 0-1;life expectancy is longer than 3 months;

          -  The patient did not receive anti-tumor therapy within 4 weeks before enrollment;

          -  A brain metastasis patient in a stable condition for one month after anti-tumor
             therapy can be included;

          -  left ventricular ejection fraction≥50%

          -  Lab test results meet the following requirements:

        white blood cell count≥3.0×10^9/L; absolute neutrophil count≥1.5 ×10^9/L (No human
        granulocyte colony stimulating factor support); blood platelet≥75 ×10^9/L;
        Hemoglobin≥10g/dL (No transfusion in the last 7 days); Prothrombin time or International
        normalized rate ≤1.5×normal upper limit, except taking anticoagulant therapy; thrombin
        time≤1.5×normal upper limit, except taking anticoagulant therapy; a 24-hour creatinine
        clearance rate≥60mL/ min; Aspartate transaminase / serum glutamic oxaloacetic
        transaminase≤2.5 ×upper limit of normal; Alanine aminotransferase/ serum glutamate pyruvate
        transaminase≤2.5 ×upper limit of normal; total bilirubin≤1.5×upper limit of normal (expect
        that the subject has Gilbert's syndrome).

          -  no pregnant women；female patients must use contraceptive measures during the study and
             prohibit any homosexual or heterosexual;

          -  The patients can regularly visit the research institutions for related tests,
             evaluations, and management during the study period.

        Exclusion Criteria:

          -  lung cancer ;

          -  received major surgery, conventional chemotherapy, large-area radiotherapy, immune
             therapy or any biological anti-tumor therapy 4 weeks before enrollment;

          -  allergic to ingredients in this trial;

          -  common terminology criteria for adverse events ≥2 because of the previous surgery or
             treatment-related adverse reactions;

          -  with two types of primary solid tumors;

          -  poorly managed hypertension (systolic blood pressure >160 mmHg and / or diastolic
             blood pressure > 90 mmHg) or clinically serious (for example, active) cerebrovascular
             diseases such as cerebrovascular incident (within 6 months prior to signing the
             informed consent), myocardial infarction (within 6 months prior to signing the
             informed consent), unstable angina, grade II or above heart failure according to New
             York Heart Association Grading Congestive, or severe arrhythmia can not be controlled
             by medication or has a potential impact on the study; with consecutive three times of
             obvious abnormality on electrocardiogram or average QT corrected interval ≥450
             millisecond;

          -  combined with other serious organic and mental disorders;

          -  serious or active bacteria, viral or fungal infections that require systemic
             treatment;

          -  with autoimmune diseases: such as a history of inflammatory bowel disease or other
             autoimmune diseases determined by the investigator as unsuitable for the study (e.g.
             systemic lupus erythematosus,vasculitis, invasive pulmonary disease);

          -  within 4 weeks prior the infusion, received chronic systemic steroid cortisone,
             hydroxyurea, immunomodulatory treatment (for example: Interleukin 2, alpha or gamma
             interferon, granulocyte colony stimulating factor, mammalian target of rapamycin
             inhibitors, cyclosporine, Thymosin etc);

          -  with organ transplantation, autologous/allogeneic stem cell transplantation and renal
             replacement therapy;

          -  with central nervous system metastasis but not receive treatment;

          -  with uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung
             disease, or liver failure;

          -  alcohol and / or drug abuse;

          -  pregnant or lactating women;

          -  received concomitant medication prohibited by this trial;

          -  with any medical condition or disease determined by the investigators that may be
             detrimental to this trial;

          -  without legal capacity / limited behavior.